Followers | 222 |
Posts | 13853 |
Boards Moderated | 0 |
Alias Born | 08/12/2011 |
Friday, May 24, 2019 2:46:50 PM
Let's think about the coming opportunities IF OWCP study can show the MGC-ODT superiority over the other.
Study Description
This is a preliminary study designed to assess the safety and properties of a new oral formulation containing the two most common cannabinoids used for medicinal purposes - Tetrahydrocannabinol (THC) and Cannabidiol (CBD). The formulation is designed to disintegrate sublingually in order to enhance absorption of these ingredients by circumventing first-pass metabolism by the liver (and probably also by the intestinal mucosal cells) as well as gastric acid degradation, thus allowing a rapid onset and more intensive pharmacological effect.
Study Design
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 16 participants
Primary Purpose: Treatment
ClinicalTrials.gov Identifier: NCT03936907
Other Study ID Numbers: OWC-ODP12
Official Title: A Single-Dose, Randomized, Crossover Study to Compare the Safety, Tolerability and Pharmacokinetics of Medical Grade Cannabis - Orally Disintegrating Tablets (MGC-ODT) With Buccal Sativex®, in Healthy Adult Volunteers
Actual Study Start Date : April 15, 2019
Estimated Primary Completion Date : July 2019
Estimated Study Completion Date : July 2019
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel (isr), Israel, 6423906
Contact: Nurit Platner, MA 972-3-6974961
Primary Outcome Measures
Pharmacokinetic parameter- Tmax determined from plasma concentrations of THC, 11-hydroxy-THC and CBD. [ Time Frame: 24 hours post dosing ]
he amount of time requires for THC, 11-hydroxy-THC and CBD to reach to maximum concentration in serum
Pharmacokinetic parameter -Cmax determined from plasma concentrations of THC, 11-hydroxy-THC and CBD. [ Time Frame: 24 hours post dosing ]
Mean highest observed plasma concentration of THC, 11-hydroxy-THC and CBD after dosing.
Pharmacokinetic parameter- AUC0-t (area under the plasma concentration-time curve) determined from plasma concentrations of THC, 11-hydroxy-THC and CBD. [ Time Frame: 24 hours post dosing ]
Pharmacokinetic parameter- T½ determined from plasma concentrations of THC, 11-hydroxy-THC and CBD. [ Time Frame: 24 hours post dosing ]
The time required for the concentration of THC, 11-hydroxy-THC and CBD to reach half of its original value
Pharmacokinetic parameter- kel determined from plasma concentrations of THC, 11-hydroxy-THC and CBD. [ Time Frame: 24 hours post dosing ]
Elimination rate constant K - The rate at which THC, 11-hydroxy-THC and CBD are removed from the body determined by their plasma concentration.
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerabilityof MGC-ODTand Sativex® ] [ Time Frame: 2 weeks post dosing ]
Safety
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM